

Influenza (2018 – 2019)

U.S. Influenza Vaccine Products for the 2018-19 Season

Trivalent (IIV3) Inactivated Influenza Vaccines

- A/Michigan/45/2015 (H1N1) pdm09–like virus
- B/Colorado/06/2017–like virus (Victoria lineage)
- A/Singapore/INFIMH-16-0019/2016 (H3N2)–like virus

Vaccine, Manufacturer	Recommended Age	Dosage
Afluria, <i>Seqirus</i>	≥5 yrs	0.5 mL IM
Fluad, <i>Seqirus</i> (allIV3)	≥65 years	0.5 mL IM
Fluzone High-Dose, <i>Sanofi Pasteur</i> (HD-IIV3)	≥65 years	0.5 mL IM

Quadrivalent (IIV4s) Inactivated Influenza Vaccines

Same components as trivalent vaccine above; and, a B/Phuket/3073/2013-like virus (Yamagata lineage)

Fluarix Quadrivalent, <i>GlaxoSmithKline</i>	≥6 months	0.5 mL IM
FluLaval Quadrivalent, <i>ID Biomedical Corp. of Quebec</i>	≥6 months	0.5 mL IM
Fluzone Quadrivalent, <i>Sanofi Pasteur</i>	6-35 months	0.25 mL IM
	≥3 yrs	0.5 mL IM
Flucelvax Quadrivalent, <i>Seqirus</i>	≥4 yrs	0.5 mL IM
Afluria Quadrivalent, <i>Seqirus</i>	≥5 yrs	0.5 mL IM
	18-64 years only	Pharmajet Stratis Jet injector

Quadrivalent Recombinant Influenza Vaccine (RIV4)

Flublok Quadrivalent, <i>Sanofi Pasteur</i>	≥18 yrs	0.5 mL IM
---	---------	-----------

Live Attenuated Influenza Vaccine (LAIV4)

FluMist Quadrivalent, <i>AstraZeneca</i>	2 – 49 years (healthy, non-pregnant)	0.2 mL intranasal (0.1 mL in each nostril)
--	---	---

Advisory Committee on Immunization Practices (ACIP) General Recommendations¹

- Offer vaccination during routine health care visits and hospitalizations to prevent missed opportunities for vaccination.
- All persons aged ≥6 months should receive an annual influenza vaccination unless contraindicated.
- The ACIP recommends the use of LAIV during the 2018 – 19 influenza season.
- Persons with a history of egg allergy of any severity may receive any licensed, recommended, and age-appropriate influenza vaccine (IIV, RIV4, or LAIV4). IIV and RIV4 have been previously recommended (See Figure 1).
- Children aged 6 months through 8 years receiving influenza vaccine for the first time should receive two doses at least 4 weeks apart (See Figure 2).
- Per [California Law](#), pregnant women and children under 3 years should receive preservative-free influenza vaccine. Flu vaccine supplied in multidose vials should not be used for this population.

IP-B71-FLU-V3 (09/13/18)



Influenza (2018 – 2019)

Persons at Increased Risk for Medical Complications Attributable to Influenza:

- All children aged 6 through 59 months
- Persons aged ≥ 50 years
- Persons who have chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)
- Persons who are immunosuppressed (including immunosuppression caused by medications or HIV)
- Pregnant women or women who will be pregnant during the influenza season
- Children and adolescents 6 months-18 years who are receiving long-term aspirin therapy
- Residents of nursing homes and other long-term care facilities;
- American Indians/Alaska Natives; and
- Persons who are extremely obese (body mass index ≥ 40).

Vaccine	IIV, RIV	LAIV
Contraindications¹	<ul style="list-style-type: none"> • History of severe allergic reaction to any vaccine component • Children <6 months of age 	<ul style="list-style-type: none"> • History of severe allergic reaction to any component to the vaccine or after a previous dose of any flu vaccine • Concomitant aspirin or salicylate-containing therapy in children and adolescents • Children aged 2 through 4 years who have asthma or who have had a wheezing episode noted in the medical record within the past 12 months, or for whom parents report that a health care provider stated that they had wheezing or asthma • Persons who are immunosuppressed (including immunosuppression caused by medications or HIV) • Close contacts and caregivers of severely immunosuppressed persons who require a protected environment; • Pregnancy • Receipt of influenza antiviral medication within previous 48 hours
Precautions¹	<ul style="list-style-type: none"> • Development of Guillain-Barré within 6 weeks of receiving a flu vaccine previously • Moderate to severe illness with or without a fever 	<ul style="list-style-type: none"> • Moderate or severe illness with or without fever • History of Guillain – Barré within 6 weeks of receiving influenza vaccine • Asthma in persons ≥ 5 years • Other underlying medical conditions that might predispose to complications after influenza infection (e.g. chronic pulmonary, cardiovascular (except hypertension), renal, hepatic, neurologic, hematologic, or, metabolic disorders, including diabetes)
Adverse Reactions²⁻¹⁰	<ul style="list-style-type: none"> • Injection site: pain redness, swelling • Systemic: fever, aches, headache, fatigue (usually begin soon after the shot and last 1-2 days), itching, bruising, irritability, abnormal crying, appetite loss, vomiting, drowsiness 	<p>Children and adolescents aged 2-17 years of age have reported:</p> <ul style="list-style-type: none"> • Runny nose, nasal congestion or cough • Fever, headache and muscle aches • Wheezing • Abdominal pain or occasional vomiting or diarrhea <p>Some adults 18-49 years of age have reported:</p> <ul style="list-style-type: none"> • Runny nose or nasal congestion • Sore throat • Cough, chills, tiredness/weakness • Headache



Influenza (2018 – 2019)

Adapted from 2018-19 ACIP Influenza Vaccine Recommendations for Persons Who Report Allergy to Eggs. ^{§§} Persons with a history of severe allergic reaction to eggs (i.e. any symptoms other than hives) should be vaccinated in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, health departments, and physician offices), under the supervision of a health care provider who is able to recognize and manage severe allergic conditions





Figure 2: Influenza vaccine dosing algorithm for children 6 months – 8 years
ACIP- United States, 2018 – 19 Influenza Season



Influenza (2018 – 2019)

References

1. Centers for Disease Control & Prevention. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 Influenza Season. Retrieved on 9/13/18 at <https://www.cdc.gov/mmwr/volumes/67/rr/rr6703a1.htm>
2. Afluria Quadrivalent Adverse Reactions (package insert). Seqirus USA Inc.; July 2017. Retrieved on 9/18/18 from <https://flu.seqirus.com/afluria-q/>
3. Afluria Trivalent-Adverse Reactions (package insert). Retrieved on 9/18/18 from <https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM518295.pdf>
4. FLUAD Adverse Reactions (package insert). Cambridge, MA. Retrieved on 9/18/18 from <https://flu.seqirus.com/fluad/>
5. FLUARIX QUADRIVALENT (package insert). Retrieved on 9/18/18 from https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Fluarix_Quadrivalent/pdf/FLUARIX-QUADRIVALENT.PDF
6. Flublok Quadrivalent Adverse Reactions. Retrieved on 9/18/18 from https://www.vaccineshoppe.com/image.cfm?doc_id=14055&image_type=product_pdf
7. FLUCELVAX QUADRIVALENT (package insert). Holly Springs, NC. Seqirus, Inc: 2016. Retrieved on 9/18/18 from <https://flu.seqirus.com/flucelvax/>
8. FluLaval Quadrivalent (package insert). Retrieved on 9/18/18 from <https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM619548.pdf>
9. Fluzone Quadrivalent (package insert). Retrieved on 9/18/18 from https://www.vaccineshoppe.com/image.cfm?doc_id=14052&image_type=product_pdf
10. Fluzone High-Dose (package insert). Retrieved on 9/18/18 from https://www.vaccineshoppe.com/image.cfm?doc_id=14054&image_type=product_pdf